Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
CDC’s website is being modified to comply with President Trump’s Executive Orders.
Volume 28, Number 6—June 2022
Dispatch

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine

Marcela Helena Gambim FonsecaComments to Author , Ana Carolina Matias Dinelly Pinto, Maria Francilene Souza Silva, Amanda Campelo Lima de Melo, Germana Silva Vasconcelos, Eduardo Ruback dos Santos, Fernanda Montenegro de Carvalho Araújo, and Luiz Odorico Monteiro de Andrade
Author affiliation: Fundação Oswaldo Cruz, Eusébio, Brazil

Main Article

Figure 2

Comparison of antibody response over time among healthcare workers vaccinated with 2 doses of CoronaVac vaccine (https://www.sinovac.com) followed by a BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com) booster dose, by COVID-19 positivity status. A) S and N IgG seropositivity. B) S IgG levels. C) N IgG levels. Antibody responses were evaluated before vaccination (timepoint P1); 28 days after the first dose of CoronaVac vaccine (P2); 30 (P3) 90 (P4), 180 (P5), and 230 (P6) days after the second dose of CoronaVac vaccine; and 15 days after the booster dose with BNT162b2 vaccine (P7). For panels B and C, black lines indicate median levels values and error bars interquartile ranges; the horizontal dotted line indicates the cutoff value of the assays. Numbers below p values indicate numbers of COVID-19–positive and COVID-19–negative persons in each timepoint. Statistical analysis performed using the Kruskal–Wallis test with subsequent Dunn’s multiple testing correction. N, nucleocapsid protein; S, spike protein; S/CO, signal-to-cutoff ratio; (–), COVID-19 negative; (+), COVID-19 positive.

Figure 2. Comparison of antibody response over time among healthcare workers vaccinated with 2 doses of CoronaVac vaccine (https://www.sinovac.com) followed by a BNT162b2 vaccine (Pfizer-BioNTech, https://www.pfizer.com) booster dose, by COVID-19 positivity status. A) S and N IgG seropositivity. B) S IgG levels. C) N IgG levels. Antibody responses were evaluated before vaccination (timepoint P1); 28 days after the first dose of CoronaVac vaccine (P2); 30 (P3) 90 (P4), 180 (P5), and 230 (P6) days after the second dose of CoronaVac vaccine; and 15 days after the booster dose with BNT162b2 vaccine (P7). For panels B and C, black lines indicate median levels values and error bars interquartile ranges; the horizontal dotted line indicates the cutoff value of the assays. Numbers below p values indicate numbers of COVID-19–positive and COVID-19–negative persons in each timepoint. Statistical analysis performed using the Kruskal–Wallis test with subsequent Dunn’s multiple testing correction. N, nucleocapsid protein; S, spike protein; S/CO, signal-to-cutoff ratio; (–), COVID-19 negative; (+), COVID-19 positive.

Main Article

Page created: March 11, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external